Mabion S.A., a biopharmaceutical company, provides contract development, analytics, and manufacturing services for biologics in Poland. It offers drug substance manufacturing, process development, analytics, and cell line development services. The company also provides medicines for cancer, autoimmune diseases, rare diseases, and other diseases. The company was founded in 2007 and is headquartered in Konstantynów Lódzki, Poland.
Research context
Mabion S.A. appears in PyInvesting’s Warsaw Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- PLN
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 7 months ago
Mabion S.A. is currently in a long term uptrend where the price is trading 53.2% above its 200 day moving average.
Its net income has increased by 45.5% to $-9M since the same quarter in the previous year.
Finally, its free cash flow grew by 10.2% to $-29M since the same quarter in the previous year.
Based on the above factors, Mabion S.A. gets an overall score of 3/5.